Core Indicators for Monitoring the Ending the HIV Epidemic Initiative (Preliminary Data):
Core Indicators for Monitoring the Ending the HIV Epidemic Initiative (Preliminary Data) :
HIV Diagnoses and Linkage to HIV Medical Care, 2019 and 2020 (Reported through June 2020)
This issue of HIV Surveillance Data Tables is published by the Division of HIV/AIDS Prevention (DHAP), National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, Georgia.
Data are presented for diagnoses of HIV infection reported to CDC through June 2020.
HIV Surveillance Data Tables is not copyrighted and may be used and copied without permission. Citation of the source is, however, appreciated.
Suggested Citation
Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative : HIV diagnoses and linkage to HIV medical care, 2019 and 2020 (preliminary data reported through June 2020). HIV Surveillance Data Tables 2020;1(No. 6) http://www.cdc.gov/hiv/library/reports/surveillance-data-tables/vol-1-no-6/index.html. Published October 2020. Accessed [date].
The Ending the HIV Epidemic: A Plan for America (EHE) initiative will leverage critical scientific advances in HIV prevention, diagnosis, treatment, and outbreak response [1]. The goal of the initiative is to reduce new HIV infections by 75% in 5 years and by at least 90% in 10 years. Throughout the initiative, the Centers for Disease Control and Prevention (CDC) will routinely release HIV Surveillance Data Tables on the 6 core indicators for EHE to allow for more timely monitoring of progress. The full list of EHE core indicators and their definitions can be found in the Technical Notes of the Core Indicators for Monitoring the Ending the HIV Epidemic Initiative report at https://www.cdc.gov/hiv/library/reports/surveillance-data-tables/vol-1-no-1/index.html.
The tables included in this report provide preliminary data on HIV diagnoses and linkage to HIV medical care reported to CDC as of June 2020 for the years 2019 and 2020. Data for both indicators are provided at the national-, state-, and county-levels (EHE Phase I jurisdictions only). See Tabulation and Presentation of Data for details on how the indicators are calculated. Data reported to the National HIV Surveillance System (NHSS) are considered preliminary until a 12-month reporting lag has been reached. Because the data in this report are provided by using an NHSS dataset produced prior to reaching a 12-month reporting lag, the data should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions [2].
Tabulation and Presentation of Data
Diagnosis of HIV Infection
Diagnoses of HIV infection are the numbers of persons aged ≥13 years whose HIV infection was diagnosed during January 2019 through June 2020 (Tables 1a–d).
Data presented were reported (after the removal of personally identifiable information) to CDC’s NHSS through June 2020. Please use caution when interpreting data on diagnoses of HIV infection. HIV surveillance reports may not be representative of all persons with HIV because not all infected persons have been (1) tested or (2) tested at a time when the infection could be detected and diagnosed. Also, some states offer anonymous HIV testing; the results of anonymous tests are not reported to the confidential, name-based HIV registries of state and local health departments. Therefore, reports of confidential test results may not represent all persons who tested positive for HIV infection.
Data reported to NHSS are considered preliminary until a 12-month reporting lag has been reached and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state and local jurisdictions.
More information on counting diagnoses of HIV infection can be found at https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-31/index.html (HIV Surveillance Report, 2018 [Updated]).
Linkage to HIV Medical Care
Linkage to HIV medical care within 1 month of HIV diagnosis is measured for persons aged ≥13 years whose HIV infection was diagnosed during January 2019 through March 2020, and who resided in any of the jurisdictions (including EHE Phase I jurisdictions) with complete reporting of laboratory data to CDC at the time of diagnosis (Tables 2a–c). The numerator is the number of persons aged ≥ 13 years whose HIV infection was diagnosed during the specified year and who had ≥1 CD4 or viral load (VL) test within 1 month of HIV diagnosis. The denominator is the number of persons aged ≥13 years whose HIV infection was diagnosed during the specified year. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting lag to account for delays in reporting of laboratory results to NHSS; therefore, data for the year 2020 on linkage to HIV medical care in these surveillance tables are for persons with HIV diagnosed during January through March of 2020 and that were reported to NHSS through June 2020. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho, New Jersey, and Pennsylvania. Areas with incomplete reporting: Arizona, Arkansas, Connecticut, Kansas, Kentucky, Vermont, and Puerto Rico.
Data reported to NHSS are considered preliminary until a 12-month reporting lag has been reached and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state and local jurisdictions.
More information on calculating linkage to care can be found at Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2018. pdf icon[PDF – 4 MB]
References
- HHS. What is ‘Ending the HIV Epidemic: A Plan for America’ https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overviewexternal icon. Published October 4, 2019. Accessed July 13, 2020.
- CDC [Schuchat A, CDC COVID-19 Response Team]. Public Health Response to the Initiation and Spread of Pandemic COVID-19 in the United States, February 24–April 21, 2020. MMWR 2020;69(18):551–556. doi: http://dx.doi.org/10.15585/mmwr.mm6918e2external icon
Suggested Citation
Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative : HIV diagnoses and linkage to HIV medical care, 2019 and 2020 (preliminary data reported through June 2020). HIV Surveillance Data Tables 2020;1(No. 6) http://www.cdc.gov/hiv/library/reports/surveillance-data-tables/vol-1-no-6/index.html. Published October 2020. Accessed [date].
Acknowledgments
Publication of HIV Surveillance Data Tables was made possible by the contributions of the state and territorial health departments and the HIV surveillance programs that provided surveillance data to CDC.
HIV Surveillance Data Tables was prepared by the following staff and contractors of the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC: Anna Satcher Johnson, Zanetta Gant, Xiaohong Hu, Jianmin Li, Baohua Wu, Chan Jin, Shihua Wang, Chenchen Yu, Irene Hall, Norma Harris, Michael Friend and the Web and Consumer Services Team of the Prevention Communications Branch (editing and desktop publishing).
| 2019 | 2020 (January – June) | |
|---|---|---|
| Total No. | Total No. | |
| Gender | ||
| Male | 28,217 | 8,292 |
| Female | 6,721 | 1,946 |
| Transgender male-to-femalea | 575 | 164 |
| Transgender female-to-malea | 41 | 8 |
| Additional gender identityb | 20 | 4 |
| Age at diagnosis (yr) | ||
| 13–24 | 7,384 | 2,063 |
| 25–34 | 12,788 | 3,797 |
| 35–44 | 6,935 | 1,995 |
| 45–54 | 4,764 | 1,437 |
| ≥55 | 3,703 | 1,122 |
| Race/ethnicity | ||
| American Indian/Alaska Native | 210 | 58 |
| Asian | 731 | 210 |
| Black/African American | 15,375 | 4,710 |
| Hispanic/Latinoc | 9,384 | 2,528 |
| Native Hawaiian/other Pacific Islander | 68 | 23 |
| White | 9,028 | 2,752 |
| Multiple races | 778 | 133 |
| Transmission categoryd | ||
| Male-to-male sexual contact | 23,574 | 7,017 |
| Injection drug use | ||
| Male | 1,349 | 411 |
| Female | 1,079 | 288 |
| Male-to-male sexual contact and injection drug use | 1,314 | 339 |
| Heterosexual contacte | ||
| Male | 2,538 | 683 |
| Female | 5,656 | 1,653 |
| Otherf | ||
| Male | 34 | 10 |
| Female | 31 | 14 |
| Region of residenceg | ||
| Northeast | 5,257 | 1,243 |
| Midwest | 4,745 | 1,447 |
| South | 18,516 | 5,797 |
| West | 7,056 | 1,927 |
| Total | 35,574 | 10,414 |
Abbreviations: CDC, the Centers for Disease Control and Prevention [footnotes only].
Note. Data are for cases reported to CDC through June 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions.
a Transgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
b Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
c Hispanics/Latinos can be of any race.
dData have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total. Data presented based on sex at birth and may include transgender persons.
eHeterosexual contact with a person known to have, or to be at high risk for, HIV infection
fIncludes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.
g Data are based on residence at time of diagnosis of HIV infection.
| 2019 | 2020 (January – June) | |
|---|---|---|
| Total No. | Total No. | |
| Gender | ||
| Male | 28,530 | 8,353 |
| Female | 6,796 | 1,953 |
| Transgender male-to-femalea | 577 | 165 |
| Transgender female-to-malea | 41 | 8 |
| Additional gender identityb | 20 | 4 |
| Age at diagnosis (yr) | ||
| 13–24 | 7,442 | 2,075 |
| 25–34 | 12,894 | 3,821 |
| 35–44 | 7,011 | 2,006 |
| 45–54 | 4,830 | 1,447 |
| ≥55 | 3,787 | 1,134 |
| Race/ethnicity | ||
| American Indian/Alaska Native | 210 | 58 |
| Asian | 737 | 210 |
| Black/African American | 15,380 | 4,710 |
| Hispanic/Latinoc | 9,752 | 2,596 |
| Native Hawaiian/other Pacific Islander | 72 | 23 |
| White | 9,034 | 2,753 |
| Multiple races | 779 | 133 |
| Transmission categoryd | ||
| Male-to-male sexual contact | 23,789 | 7,062 |
| Injection drug use | ||
| Male | 1,377 | 419 |
| Female | 1,084 | 288 |
| Male-to-male sexual contact and injection drug use | 1,325 | 341 |
| Heterosexual contacte | ||
| Male | 2,599 | 690 |
| Female | 5,726 | 1,659 |
| Otherf | ||
| Male | 34 | 10 |
| Female | 31 | 14 |
| Region of residenceg | ||
| Northeast | 5,257 | 1,243 |
| Midwest | 4,745 | 1,447 |
| South | 18,516 | 5,797 |
| West | 7,056 | 1,927 |
| U.S. dependent areas | 390 | 69 |
| Total | 35,964 | 10,483 |
Abbreviations: CDC, the Centers for Disease Control and Prevention [footnotes only].
Note. Data are for cases reported to CDC through June 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions.
a “Transgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
b Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
c Hispanics/Latinos can be of any race.
dData have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total. Data presented based on sex at birth and may include transgender persons.
eHeterosexual contact with a person known to have, or to be at high risk for, HIV infection
fIncludes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.
g Data are based on residence at time of diagnosis of HIV infection.
| 2019 | 2020 (January – June) | |
|---|---|---|
| Area of residence | Total No. | Total No. |
| Alabama | 596 | 221 |
| Alaska | 27 | 15 |
| Arizona | 766 | 290 |
| Arkansas | 284 | 120 |
| California | 4,198 | 1,061 |
| Colorado | 459 | 117 |
| Connecticut | 212 | 40 |
| Delaware | 92 | 48 |
| District of Columbia | 249 | 62 |
| Florida | 4,405 | 1,648 |
| Georgia | 2,291 | 524 |
| Hawaii | 63 | 12 |
| Idaho | 27 | 1 |
| Illinois | 1,257 | 290 |
| Indiana | 490 | 178 |
| Iowa | 100 | 35 |
| Kansas | 132 | 38 |
| Kentucky | 268 | 57 |
| Louisiana | 889 | 331 |
| Maine | 29 | 4 |
| Maryland | 917 | 277 |
| Massachusetts | 521 | 95 |
| Michigan | 675 | 213 |
| Minnesota | 273 | 100 |
| Mississippi | 460 | 172 |
| Missouri | 487 | 168 |
| Montana | 25 | 3 |
| Nebraska | 81 | 26 |
| Nevada | 509 | 85 |
| New Hampshire | 31 | 11 |
| New Jersey | 1,029 | 140 |
| New Mexico | 147 | 31 |
| New York | 2,340 | 659 |
| North Carolina | 1,376 | 499 |
| North Dakota | 36 | 9 |
| Ohio | 972 | 302 |
| Oklahoma | 243 | 62 |
| Oregon | 198 | 69 |
| Pennsylvania | 1,010 | 276 |
| Rhode Island | 74 | 12 |
| South Carolina | 702 | 282 |
| South Dakota | 34 | 8 |
| Tennessee | 776 | 284 |
| Texas | 4,002 | 882 |
| Utah | 135 | 48 |
| Vermont | 11 | 6 |
| Virginia | 822 | 281 |
| Washington | 489 | 191 |
| West Virginia | 144 | 47 |
| Wisconsin | 208 | 80 |
| Wyoming | 13 | 4 |
| Subtotal | 35,574 | 10,414 |
| U.S. dependent areas | ||
| American Samoa | 0 | 0 |
| Guam | 10 | 0 |
| Northern Mariana Islands | 2 | 0 |
| Puerto Rico | 372 | 69 |
| Republic of Palau | 0 | 0 |
| U.S. Virgin Islands | 6 | 0 |
| Subtotal | 390 | 69 |
| Total | 35,964 | 10,483 |
Abbreviations: CDC, the Centers for Disease Control and Prevention [footnotes only].
Note. Data are based on residence at time of diagnosis of HIV infection. Data are for cases reported to CDC through June 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions.
| 2019 | 2020 (January – June) | |
|---|---|---|
| Area of residence | Total No. | Total No. |
| Arizona | ||
| Maricopa County | 525 | 196 |
| California | ||
| Alameda County | 223 | 73 |
| Los Angeles County | 1,409 | 373 |
| Orange County | 246 | 104 |
| Riverside County | 262 | 61 |
| Sacramento County | 84 | 3 |
| San Bernardino County | 273 | 33 |
| San Diego County | 361 | 66 |
| San Francisco County | 207 | 62 |
| District of Columbia | 249 | 62 |
| Florida | ||
| Broward County | 598 | 218 |
| Duval County | 272 | 98 |
| Hillsborough County | 267 | 136 |
| Miami-Dade County | 1,158 | 378 |
| Orange County | 471 | 183 |
| Palm Beach County | 237 | 102 |
| Pinellas County | 187 | 83 |
| Georgia | ||
| Cobb County | 170 | 27 |
| DeKalb County | 327 | 64 |
| Fulton County | 565 | 145 |
| Gwinnett County | 194 | 32 |
| Illinois | ||
| Cook County | 893 | 213 |
| Indiana | ||
| Marion County | 209 | 70 |
| Louisiana | ||
| East Baton Rouge Parish | 152 | 63 |
| Orleans Parish | 159 | 42 |
| Maryland | ||
| Baltimore City | 192 | 64 |
| Montgomery County | 141 | 37 |
| Prince George’s County | 271 | 77 |
| Massachusetts | ||
| Suffolk County | 134 | 31 |
| Michigan | ||
| Wayne County | 285 | 99 |
| Nevada | ||
| Clark County | 448 | 64 |
| New Jersey | ||
| Essex County | 224 | 43 |
| Hudson County | 148 | 18 |
| New York | ||
| Bronx County | 500 | 119 |
| Kings County | 474 | 160 |
| New York County | 343 | 103 |
| Queens County | 356 | 109 |
| North Carolina | ||
| Mecklenburg County | 268 | 82 |
| Ohio | ||
| Cuyahoga County | 158 | 59 |
| Franklin County | 217 | 79 |
| Hamilton County | 171 | 41 |
| Pennsylvania | ||
| Philadelphia County | 431 | 112 |
| Tennessee | ||
| Shelby County | 262 | 108 |
| Texas | ||
| Bexar County | 356 | 112 |
| Dallas County | 738 | 257 |
| Harris County | 1,100 | 120 |
| Tarrant County | 292 | 78 |
| Travis County | 180 | 58 |
| Washington | ||
| King County | 252 | 106 |
| Puerto Rico | ||
| San Juan Municipio | 85 | 13 |
Abbreviations: CDC, the Centers for Disease Control and Prevention [footnotes only].
Note. Data are based on residence at time of diagnosis of HIV infection. Data are for cases reported to CDC through June 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions.
| 2019 | 2020 (January – March) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total diagnoses | ≥1 CD4 or VL tests | No CD4 or VL test | Total diagnoses | ≥1 CD4 or VL tests | No CD4 or VL test | |||||
| No. | No. | % | No. | % | No. | No. | % | No. | % | |
| Gender | ||||||||||
| Male | 25,292 | 20,727 | 82.0 | 4,565 | 18.0 | 5,370 | 4,349 | 81.0 | 1,021 | 19.0 |
| Female | 5,966 | 4,783 | 80.2 | 1,183 | 19.8 | 1,224 | 998 | 81.5 | 226 | 18.5 |
| Transgender male-to-femalea | 523 | 434 | 83.0 | 89 | 17.0 | 106 | 88 | 83.0 | 18 | 17.0 |
| Transgender female-to-malea | 36 | 31 | 86.1 | 5 | 13.9 | 4 | 4 | 100 | 0 | 0.0 |
| Additional gender identityb | 18 | 16 | 88.9 | 2 | 11.1 | 3 | 3 | 100 | 0 | 0.0 |
| Age at diagnosis (yr) | ||||||||||
| 13–24 | 6,618 | 5,264 | 79.5 | 1,354 | 20.5 | 1,318 | 1,024 | 77.7 | 294 | 22.3 |
| 25–34 | 11,471 | 9,303 | 81.1 | 2,168 | 18.9 | 2,441 | 1,987 | 81.4 | 454 | 18.6 |
| 35–44 | 6,213 | 5,134 | 82.6 | 1,079 | 17.4 | 1,326 | 1,076 | 81.1 | 250 | 18.9 |
| 45–54 | 4,246 | 3,542 | 83.4 | 704 | 16.6 | 922 | 760 | 82.4 | 162 | 17.6 |
| ≥55 | 3,287 | 2,748 | 83.6 | 539 | 16.4 | 700 | 595 | 85.0 | 105 | 15.0 |
| Race/ethnicity | ||||||||||
| American Indian/Alaska Native | 167 | 140 | 83.8 | 27 | 16.2 | 34 | 29 | 85.3 | 5 | 14.7 |
| Asian | 661 | 548 | 82.9 | 113 | 17.1 | 140 | 121 | 86.4 | 19 | 13.6 |
| Black/African American | 14,005 | 11,060 | 79.0 | 2,945 | 21.0 | 3,080 | 2,432 | 79.0 | 648 | 21.0 |
| Hispanic/Latinoc | 8,380 | 7,080 | 84.5 | 1,300 | 15.5 | 1,636 | 1,352 | 82.6 | 284 | 17.4 |
| Native Hawaiian/other Pacific Islander | 64 | 52 | 81.3 | 12 | 18.8 | 14 | 11 | 78.6 | 3 | 21.4 |
| White | 7,849 | 6,518 | 83.0 | 1,331 | 17.0 | 1,707 | 1,416 | 83.0 | 291 | 17.0 |
| Multiple races | 709 | 593 | 83.6 | 116 | 16.4 | 96 | 81 | 84.4 | 15 | 15.6 |
| Transmission categoryd | ||||||||||
| Male-to-male sexual contact | 21,288 | 17,558 | 82.5 | 3,729 | 17.5 | 4,556 | 3,694 | 81.1 | 862 | 18.9 |
| Injection drug use | ||||||||||
| Male | 1,108 | 854 | 77.1 | 253 | 22.9 | 256 | 199 | 77.5 | 58 | 22.5 |
| Female | 927 | 702 | 75.7 | 225 | 24.3 | 181 | 147 | 80.9 | 35 | 19.1 |
| Male-to-male sexual contact and injection drug use | 1,152 | 926 | 80.4 | 225 | 19.6 | 216 | 179 | 82.7 | 37 | 17.3 |
| Heterosexual contacte | ||||||||||
| Male | 2,251 | 1,808 | 80.3 | 443 | 19.7 | 446 | 365 | 81.8 | 81 | 18.2 |
| Female | 5,052 | 4,091 | 81.0 | 961 | 19.0 | 1,036 | 846 | 81.6 | 191 | 18.4 |
| Totalf | 31,835 | 25,991 | 81.6 | 5,844 | 18.4 | 6,707 | 5,442 | 81.1 | 1,265 | 18.9 |
Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL). CDC, the Centers for Disease Control and Prevention [footnotes only].
Note. Data are for cases reported to CDC through June 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Reporting of linkage to HIV medical care data requires a 3-month reporting lag to account for delays in reporting of laboratory results to CDC; therefore, data for the year 2020 on linkage to HIV medical care are for persons with HIV diagnosed during January through March of 2020, that were reported to CDC through June 2020. Data not provided for jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or for areas with incomplete reporting of laboratory data to CDC. Areas without laws: Idaho, New Jersey, and Pennsylvania. Areas with incomplete lab reporting: Arizona, Arkansas, Connecticut, Kansas, Kentucky, Vermont, and Puerto Rico.
aTransgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
bAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
cHispanics/Latinos can be of any race.
dData have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total. Data presented based on sex at birth and include transgender persons.
eHeterosexual contact with a person known to have, or to be at high risk for, HIV infection.
fIncludes persons whose infection was attributed to hemophilia, blood transfusion, or perinatal exposure or whose risk factor was not reported or not identified. Data not displayed because the numbers were too small to be meaningful.
| 2019 | 2020 (January – March) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total diagnoses | ≥1 CD4 or VL tests | No CD4 or VL test | Total diagnoses | ≥1 CD4 or VL tests | No CD4 or VL test | |||||
| No. | No. | % | No. | % | No. | No. | % | No. | % | |
| Alabama | 596 | 471 | 79.0 | 125 | 21.0 | 170 | 140 | 82.4 | 30 | 17.6 |
| Alaska | 27 | 23 | 85.2 | 4 | 14.8 | 9 | 9 | 100 | 0 | 0.0 |
| California | 4,198 | 3,474 | 82.8 | 724 | 17.2 | 844 | 737 | 87.3 | 107 | 12.7 |
| Colorado | 459 | 381 | 83.0 | 78 | 17.0 | 78 | 68 | 87.2 | 10 | 12.8 |
| Delaware | 92 | 71 | 77.2 | 21 | 22.8 | 36 | 27 | 75.0 | 9 | 25.0 |
| District of Columbia | 249 | 223 | 89.6 | 26 | 10.4 | 48 | 42 | 87.5 | 6 | 12.5 |
| Florida | 4,405 | 3,691 | 83.8 | 714 | 16.2 | 1,034 | 869 | 84.0 | 165 | 16.0 |
| Georgia | 2,291 | 1,903 | 83.1 | 388 | 16.9 | 388 | 335 | 86.3 | 53 | 13.7 |
| Hawaii | 63 | 54 | 85.7 | 9 | 14.3 | 9 | 8 | 88.9 | 1 | 11.1 |
| Illinois | 1,257 | 1,046 | 83.2 | 211 | 16.8 | 236 | 211 | 89.4 | 25 | 10.6 |
| Indiana | 490 | 305 | 62.2 | 185 | 37.8 | 116 | 79 | 68.1 | 37 | 31.9 |
| Iowa | 100 | 91 | 91.0 | 9 | 9.0 | 24 | 22 | 91.7 | 2 | 8.3 |
| Louisiana | 889 | 732 | 82.3 | 157 | 17.7 | 217 | 157 | 72.4 | 60 | 27.6 |
| Maine | 29 | 27 | 93.1 | 2 | 6.9 | 4 | 4 | 100 | 0 | 0.0 |
| Maryland | 917 | 805 | 87.8 | 112 | 12.2 | 191 | 177 | 92.7 | 14 | 7.3 |
| Massachusetts | 521 | 474 | 91.0 | 47 | 9.0 | 84 | 72 | 85.7 | 12 | 14.3 |
| Michigan | 675 | 570 | 84.4 | 105 | 15.6 | 146 | 115 | 78.8 | 31 | 21.2 |
| Minnesota | 273 | 251 | 91.9 | 22 | 8.1 | 67 | 59 | 88.1 | 8 | 11.9 |
| Mississippi | 460 | 327 | 71.1 | 133 | 28.9 | 117 | 85 | 72.6 | 32 | 27.4 |
| Missouri | 487 | 375 | 77.0 | 112 | 23.0 | 103 | 82 | 79.6 | 21 | 20.4 |
| Montana | 25 | 22 | 88.0 | 3 | 12.0 | 3 | 2 | 66.7 | 1 | 33.3 |
| Nebraska | 81 | 65 | 80.2 | 16 | 19.8 | 22 | 19 | 86.4 | 3 | 13.6 |
| Nevada | 509 | 424 | 83.3 | 85 | 16.7 | 74 | 60 | 81.1 | 14 | 18.9 |
| New Hampshire | 31 | 28 | 90.3 | 3 | 9.7 | 10 | 10 | 100 | 0 | 0.0 |
| New Mexico | 147 | 132 | 89.8 | 15 | 10.2 | 23 | 20 | 87.0 | 3 | 13.0 |
| New York | 2,340 | 2,036 | 87.0 | 304 | 13.0 | 528 | 470 | 89.0 | 58 | 11.0 |
| North Carolina | 1,376 | 1,086 | 78.9 | 290 | 21.1 | 299 | 246 | 82.3 | 53 | 17.7 |
| North Dakota | 36 | 33 | 91.7 | 3 | 8.3 | 9 | 8 | 88.9 | 1 | 11.1 |
| Ohio | 972 | 815 | 83.8 | 157 | 16.2 | 235 | 203 | 86.4 | 32 | 13.6 |
| Oklahoma | 243 | 174 | 71.6 | 69 | 28.4 | 43 | 33 | 76.7 | 10 | 23.3 |
| Oregon | 198 | 176 | 88.9 | 22 | 11.1 | 48 | 44 | 91.7 | 4 | 8.3 |
| Rhode Island | 74 | 65 | 87.8 | 9 | 12.2 | 11 | 8 | 72.7 | 3 | 27.3 |
| South Carolina | 702 | 613 | 87.3 | 89 | 12.7 | 196 | 180 | 91.8 | 16 | 8.2 |
| South Dakota | 34 | 27 | 79.4 | 7 | 20.6 | 7 | 6 | 85.7 | 1 | 14.3 |
| Tennessee | 776 | 534 | 68.8 | 242 | 31.2 | 190 | 132 | 69.5 | 58 | 30.5 |
| Texas | 4,002 | 2,971 | 74.2 | 1,031 | 25.8 | 649 | 345 | 53.2 | 304 | 46.8 |
| Utah | 135 | 105 | 77.8 | 30 | 22.2 | 36 | 18 | 50.0 | 18 | 50.0 |
| Virginia | 822 | 648 | 78.8 | 174 | 21.2 | 193 | 156 | 80.8 | 37 | 19.2 |
| Washington | 489 | 436 | 89.2 | 53 | 10.8 | 123 | 109 | 88.6 | 14 | 11.4 |
| West Virginia | 144 | 106 | 73.6 | 38 | 26.4 | 33 | 25 | 75.8 | 8 | 24.2 |
| Wisconsin | 208 | 188 | 90.4 | 20 | 9.6 | 50 | 47 | 94.0 | 3 | 6.0 |
| Wyoming | 13 | 13 | 100 | 0 | 0.0 | 4 | 3 | 75.0 | 1 | 25.0 |
| Total | 31,835 | 25,991 | 81.6 | 5,844 | 18.4 | 6,707 | 5,442 | 81.1 | 1,265 | 18.9 |
Abbreviations: CD4, CD4+ T -lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL). CDC, the Centers for Disease Control and Prevention [footnotes only].
Note. Data are based on residence at diagnosis of HIV infection. Data are for cases reported to CDC through June 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions.
Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Reporting of linkage to HIV medical care data requires a 3-month reporting lag to account for delays in reporting of laboratory results to CDC; therefore, data for the year 2020 on linkage to HIV medical care are for persons with HIV diagnosed during January through March of 2020, that were reported to CDC through June 2020. Data not provided for jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or for areas with incomplete reporting of laboratory data to CDC. Areas without laws: Idaho, New Jersey, and Pennsylvania. Areas with incomplete lab reporting: Arizona, Arkansas, Connecticut, Kansas, Kentucky, Vermont, and Puerto Rico.
| 2019 | 2020 (January – March) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total diagnoses | ≥1 CD4 or VL tests | No CD4 or VL test | Total diagnoses | ≥1 CD4 or VL tests | No CD4 or VL test | |||||
| No. | No. | % | No. | % | No. | No. | % | No. | % | |
| California | ||||||||||
| Alameda County | 223 | 199 | 89.2 | 24 | 10.8 | 49 | 43 | 87.8 | 6 | 12.2 |
| Los Angeles County | 1,409 | 1,134 | 80.5 | 275 | 19.5 | 287 | 246 | 85.7 | 41 | 14.3 |
| Orange County | 246 | 199 | 80.9 | 47 | 19.1 | 73 | 65 | 89.0 | 8 | 11.0 |
| Riverside County | 262 | 212 | 80.9 | 50 | 19.1 | 48 | 43 | 89.6 | 5 | 10.4 |
| Sacramento County | 84 | 75 | 89.3 | 9 | 10.7 | 2 | 2 | 100 | 0 | 0.0 |
| San Bernardino County | 273 | 201 | 73.6 | 72 | 26.4 | 29 | 23 | 79.3 | 6 | 20.7 |
| San Diego County | 361 | 309 | 85.6 | 52 | 14.4 | 64 | 59 | 92.2 | 5 | 7.8 |
| San Francisco County | 207 | 199 | 96.1 | 8 | 3.9 | 49 | 47 | 95.9 | 2 | 4.1 |
| District of Columbia | 249 | 223 | 89.6 | 26 | 10.4 | 48 | 42 | 87.5 | 6 | 12.5 |
| Florida | ||||||||||
| Broward County | 598 | 525 | 87.8 | 73 | 12.2 | 139 | 124 | 89.2 | 15 | 10.8 |
| Duval County | 272 | 209 | 76.8 | 63 | 23.2 | 65 | 53 | 81.5 | 12 | 18.5 |
| Hillsborough County | 267 | 229 | 85.8 | 38 | 14.2 | 75 | 64 | 85.3 | 11 | 14.7 |
| Miami-Dade County | 1,158 | 975 | 84.2 | 183 | 15.8 | 244 | 202 | 82.8 | 42 | 17.2 |
| Orange County | 471 | 372 | 79.0 | 99 | 21.0 | 108 | 93 | 86.1 | 15 | 13.9 |
| Palm Beach County | 237 | 188 | 79.3 | 49 | 20.7 | 76 | 62 | 81.6 | 14 | 18.4 |
| Pinellas County | 187 | 160 | 85.6 | 27 | 14.4 | 43 | 38 | 88.4 | 5 | 11.6 |
| Georgia | ||||||||||
| Cobb County | 170 | 151 | 88.8 | 19 | 11.2 | 16 | 14 | 87.5 | 2 | 12.5 |
| DeKalb County | 327 | 272 | 83.2 | 55 | 16.8 | 47 | 44 | 93.6 | 3 | 6.4 |
| Fulton County | 565 | 479 | 84.8 | 86 | 15.2 | 115 | 97 | 84.3 | 18 | 15.7 |
| Gwinnett County | 194 | 166 | 85.6 | 28 | 14.4 | 26 | 20 | 76.9 | 6 | 23.1 |
| Illinois | ||||||||||
| Cook County | 893 | 743 | 83.2 | 150 | 16.8 | 166 | 151 | 91.0 | 15 | 9.0 |
| Indiana | ||||||||||
| Marion County | 209 | 110 | 52.6 | 99 | 47.4 | 48 | 32 | 66.7 | 16 | 33.3 |
| Louisiana | ||||||||||
| East Baton Rouge Parish | 152 | 134 | 88.2 | 18 | 11.8 | 40 | 33 | 82.5 | 7 | 17.5 |
| Orleans Parish | 159 | 131 | 82.4 | 28 | 17.6 | 25 | 19 | 76.0 | 6 | 24.0 |
| Maryland | ||||||||||
| Baltimore City | 192 | 166 | 86.5 | 26 | 13.5 | 43 | 39 | 90.7 | 4 | 9.3 |
| Montgomery County | 141 | 129 | 91.5 | 12 | 8.5 | 24 | 24 | 100 | 0 | 0.0 |
| Prince George’s County | 271 | 238 | 87.8 | 33 | 12.2 | 55 | 51 | 92.7 | 4 | 7.3 |
| Massachusetts | ||||||||||
| Suffolk County | 134 | 123 | 91.8 | 11 | 8.2 | 27 | 26 | 96.3 | 1 | 3.7 |
| Michigan | ||||||||||
| Wayne County | 285 | 244 | 85.6 | 41 | 14.4 | 73 | 57 | 78.1 | 16 | 21.9 |
| Nevada | ||||||||||
| Clark County | 448 | 369 | 82.4 | 79 | 17.6 | 62 | 49 | 79.0 | 13 | 21.0 |
| New York | ||||||||||
| Bronx County | 500 | 435 | 87.0 | 65 | 13.0 | 88 | 75 | 85.2 | 13 | 14.8 |
| Kings County | 474 | 402 | 84.8 | 72 | 15.2 | 135 | 117 | 86.7 | 18 | 13.3 |
| New York County | 343 | 303 | 88.3 | 40 | 11.7 | 76 | 66 | 86.8 | 10 | 13.2 |
| Queens County | 356 | 304 | 85.4 | 52 | 14.6 | 92 | 88 | 95.7 | 4 | 4.3 |
| North Carolina | ||||||||||
| Mecklenburg County | 268 | 208 | 77.6 | 60 | 22.4 | 44 | 36 | 81.8 | 8 | 18.2 |
| Ohio | ||||||||||
| Cuyahoga County | 158 | 141 | 89.2 | 17 | 10.8 | 47 | 42 | 89.4 | 5 | 10.6 |
| Franklin County | 217 | 197 | 90.8 | 20 | 9.2 | 58 | 50 | 86.2 | 8 | 13.8 |
| Hamilton County | 171 | 145 | 84.8 | 26 | 15.2 | 31 | 29 | 93.5 | 2 | 6.5 |
| Pennsylvania | ||||||||||
| Philadelphia County | 431 | 367 | 85.2 | 64 | 14.8 | 94 | 80 | 85.1 | 14 | 14.9 |
| Tennessee | ||||||||||
| Shelby County | 262 | 164 | 62.6 | 98 | 37.4 | 76 | 50 | 65.8 | 26 | 34.2 |
| Texas | ||||||||||
| Bexar County | 356 | 255 | 71.6 | 101 | 28.4 | 77 | 42 | 54.5 | 35 | 45.5 |
| Dallas County | 738 | 558 | 75.6 | 180 | 24.4 | 173 | 103 | 59.5 | 70 | 40.5 |
| Harris County | 1,100 | 803 | 73.0 | 297 | 27.0 | 91 | 48 | 52.7 | 43 | 47.3 |
| Tarrant County | 292 | 218 | 74.7 | 74 | 25.3 | 63 | 33 | 52.4 | 30 | 47.6 |
| Travis County | 180 | 154 | 85.6 | 26 | 14.4 | 41 | 21 | 51.2 | 20 | 48.8 |
| Washington | ||||||||||
| King County | 252 | 227 | 90.1 | 25 | 9.9 | 60 | 52 | 86.7 | 8 | 13.3 |
Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL). CDC, the Centers for Disease Control and Prevention [footnotes only].
Note. Data are based on residence at diagnosis of HIV infection. Data are for cases reported to CDC through June 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions.
Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Reporting of linkage to HIV medical care data requires a 3-month reporting lag to account for delays in reporting of laboratory results to CDC; therefore, data for the year 2020 on linkage to HIV medical care are for persons with HIV diagnosed during January through March of 2020, that were reported to CDC through June 2020. Data not provided for jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or for areas with incomplete reporting of laboratory data to CDC. Areas without laws: Idaho, New Jersey, and Pennsylvania. Areas with incomplete lab reporting: Arizona, Arkansas, Connecticut, Kansas, Kentucky, Vermont, and Puerto Rico.